Patents Assigned to AMAL THERAPEUTICS SA
  • Patent number: 11338027
    Abstract: The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 24, 2022
    Assignee: AMAL THERAPEUTICS SA
    Inventors: Madiha Derouazi, Elodie Belnoue
  • Publication number: 20220118102
    Abstract: The present invention provides a combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, at least one antigen or antigenic epitope, and a TLR peptide agonist for use in medicine, in particular in the prevention and/or treatment of cancer. Moreover, the present invention also provides compositions, such as a pharmaceutical compositions and vaccines, which are useful in medicine, for example in the prevention and/or treatment of cancer.
    Type: Application
    Filed: January 5, 2022
    Publication date: April 21, 2022
    Applicant: AMAL THERAPEUTICS SA
    Inventors: Madiha DEROUAZI, Elodie BELNOUE
  • Publication number: 20190255165
    Abstract: The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.
    Type: Application
    Filed: September 21, 2017
    Publication date: August 22, 2019
    Applicant: Amal Therapeutics SA
    Inventors: Madiha DEROUAZI, Elodie BELNOUE
  • Publication number: 20190175748
    Abstract: The present invention provides a combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, at least one antigen or antigenic epitope, and a TLR peptide agonist for use in medicine, in particular in the prevention and/or treatment of cancer. Moreover, the present invention also provides compositions, such as a pharmaceutical compositions and vaccines, which are useful in medicine, for example in the prevention and/or treatment of cancer.
    Type: Application
    Filed: March 14, 2017
    Publication date: June 13, 2019
    Applicant: AMAL THERAPEUTICS SA
    Inventors: Madiha DEROUAZI, Elodie BELNOUE
  • Publication number: 20180133295
    Abstract: The present invention provides a novel complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. Moreover, the present invention also provides a nucleic acid encoding such a complex, wherein the complex is a peptide or a protein. Such a nucleic acid may be comprised by a vector, and such a vector may be comprised by a host cell. In particular, compositions, such as a pharmaceutical compositions and vaccines are provided, which may be useful for example in the prevention and/or treatment of a diseases and/or a disorder including cancer, hematological disorders, infectious diseases, autoimmunity disorders and transplant rejections.
    Type: Application
    Filed: March 16, 2016
    Publication date: May 17, 2018
    Applicant: AMAL THERAPEUTICS SA
    Inventors: Madiha DEROUAZI, Elodie BELNOUE
  • Publication number: 20180133339
    Abstract: The present invention provides a novel complex for use in the prevention and/or treatment of glioma, in particular glioblastoma, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of glioma, in particular glioblastoma, such as a pharmaceutical compositions and vaccines are provided.
    Type: Application
    Filed: March 16, 2016
    Publication date: May 17, 2018
    Applicant: Amal Therapeutics SA
    Inventors: Madiha DEROUAZI, Elodie BELNOUE
  • Publication number: 20180133327
    Abstract: The present invention provides a cell penetrating peptide derived from ZEBRA, which is optionally linked to a cargo molecule, such as at least one antigen or antigenic epitope. The present invention also provides a complex comprising the cell penetrating peptide and the cargo molecule. In particular, compositions, such as a pharmaceutical compositions and vaccines are provided, which may be useful for example in the prevention and/or treatment of a diseases and/or a disorder including cancer, hematological disorders, infectious diseases, autoimmunity disorders and transplant rejections.
    Type: Application
    Filed: December 22, 2015
    Publication date: May 17, 2018
    Applicant: Amal Therapeutics SA
    Inventor: Madiha DEROUAZI
  • Publication number: 20180133338
    Abstract: The present invention provides a novel complex for use in the prevention and/or treatment of colorectal cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of colorectal cancer, such as a pharmaceutical compositions and vaccines are provided.
    Type: Application
    Filed: March 16, 2016
    Publication date: May 17, 2018
    Applicant: Amal Therapeutics SA
    Inventors: Madiha DEROUAZI, Elodie BELNOUE